For more than 20 years, our teams have worked to combat this zoonotic disease that threatens the health of dogs and humans alike. In 2024, we continue to work to bring diagnostic, prevention and treatment solutions to veterinarians and dog owners in endemic areas. Our latest stop is France, which will host the Animal Leishmaniosis International Veterinary Event in Nice in April.

Building on the momentum of the second half of 2023, strong first-quarter revenue growth of +10.8% at constant exchange rates

On April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species.